Skip to main content
. 2020 Jul 27;15(7):e0235449. doi: 10.1371/journal.pone.0235449

Fig 4. Relative B cell contributions under different therapies.

Fig 4

A Displayed are the percentages of CD19+ B cells among the total circulating lymphocyte pool (gated events). B Displayed are the percentages of the circulating B cell subsets among the total CD19+ B cell pool (NIND = non-inflammatory neurological disease, UT = untreated MS patients, NAT = natalizumab, DMF = dimethyl fumarate, FTY = fingolimod, GLAT = glatiramer acteate and IFN = interferon-β treated MS patients).